Neeta Pradhan, MSc

CRS:

BJMC

Role:

Laboratory

Position:

TB Laboratory Coordinator

Email:

neetapradhanpune@gmail.com

Neeta Pradhan is TB Laboratory Coordinator at the BJGMC-CRS in Pune, India. She has worked as Laboratory Manager at Golwilkar Metropolis Health Services where she was responsible for technical and quality aspects of laboratory testing.

She worked as a Laboratory Coordinator at NARI (National AIDS Research Institute) Clinical Trial Unit for various NIH-funded clinical stuies in the HIV Prevention Trials Network (HPTN), the AIDS Clinical Trial Group (ACTG), and the Microbicide Trial Network (MTN). She was responsible for lab quality management, administration, monitoring and supervision, and coordination and communication as well as additional institutional responsibilities such as lab accreditation.

She has also handled CONDRAD (ICMR) project in the capacity of a Laboratory Coordinator at NARI. She is a NABL (National Accreditation Board for Testing & Calibration of laboratory) 15189 trained internal auditor as well as being trained at GCLP by PPD.

She completed her post graduation at BJGMC, which is affiliated with the University of Pune.

  • Voting Member, Laboratory Technologist Committee (Dec 2017-Nov 2019)
  • Member, TB Laboratory Core Team

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More